

# Reducing The Amount of Unnecessary Proton Pump Inhibitor Use After H. pylori Treatment

Basil Elamir <sup>1\*</sup>, Nermeen Kolta<sup>2</sup>, Ahmed Salem<sup>3</sup>, Yasmine Elamir<sup>4</sup>, William Grist Md<sup>5</sup>

<sup>1</sup>PGY 3 Suny DownState Medical Center, Gastroenterology Fellow Candidate

<sup>2</sup>Jersey City Breathing Center: Internal Medicine Residency Candidate

<sup>3</sup>PGY-1 Internal Medicine Carepoint Health Bayonne Medical Center

<sup>4</sup>Attending Endocrinology at Jersey City Breathing Center; Teaching Faculty Carepoint Health Bayonne Medical Center

<sup>5</sup>Pulmonary Critical Fellow St Joseph's University Medical Center

**\*Corresponding author**

Basil Elamir\*, PGY 3 Suny Down State Medical Center, Gastroenterology Fellow Candidat.

**Submitted:** 04 Aug 2022; **Accepted:** 07 Aug 2022; **Published:** 14 Aug 2022

**Citation:** Elamir. B., Kolta. N., Salem. A., Elamir. Y. (2022). Reducing The Amount of Unnecessary Proton Pump Inhibitor Use After H. pylori Treatment. *Int J Clin Med Edu Res.* 1(3), 100-101.

**Background**

H. pylori (Heliobacter pylori) is a type of bacteria that infects your stomach and leads to gastritis and gastric ulcers due to inflammation in the duodenum and upper digestive tract. After diagnosis treatment involves proton pump inhibitor (PPI) use with a 10-14 day course of antibiotics. After treatment, resolution of symptoms, and confirmed eradication of H. Pylori the use of proton pump inhibitors is generally not recommended unless certain criteria are made. Almost half of all African Americans have the bacteria. For people who come to the U.S. from developing countries, at least 50% of Latinos and 50% of people from Eastern Europe have H. pylori. (Bravo et al) Our urban primary care practice in urban Jersey City NJ has a high rate of gastritis from H. pylori. Due to our high risk population we thought it was an opportunity for quality improvement for better evidence based patient care [1].

**Goal**


Reduce PPI therapy to decrease cost to our patients, mitigate poor bone health, hypocalcemia, hypomagnesemia, Clostridium difficile infections, and pneumonia that are associated with proton pump inhibitor use [2].

Methods and Analysis: Using our electronic medical record (EMR) Lytec MD we found twenty-eight patients from January 2021-July 28th 2022 time period who were treated with confirmed H. pylori with triple or quadruple therapy. Those who were treated were then screened for the following indications for continued to treatment which included diagnosis codes for gastroesophageal reflux disease, gastritis, peptic ulcer disease, dyspepsia, persistent

H pylori, Zollinger-Ellison syndrome, and upper GI bleeding. We found that seven patients were still on PPI therapy, four of which with one of the above indications, and three without the above indications.

**Limitations**

There is a chance that more patients than reported in the study could be potentially on PPI therapy now which may not be recorded in the EMR. Summary and Solution: We found that many patients over use PPI therapy after treatment with Hpylori mostly due to poor education and background knowledge. In effort to prevent over use in the future we will be using the following sheet in follow up appointments in order to screen earlier for all patients on PPI therapy to prevent over use.



---

## References

1. Bravo, D., Hoare, A., Soto, C., Valenzuela, M. A., & Quest, A. F. (2018). Helicobacter pylori in human health and disease: Mechanisms for local gastric and systemic effects. World journal of gastroenterology, 24(28), 3071.
2. Haastrup. (2018, May 24). Basic Clinical Pharmacology Toxicology. Retrieved from pubmed.ncbi.nlm.nih.gov: <https://pubmed.ncbi.nlm.nih.gov/29658189/>

**Copyright:** © 2022 Basil Elamir. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.